Diamyd Medical’s Remygen™ for regeneration of insulin-producing cells approved for clinical trials

The Swedish Medical Products Agency has approved the initiation of the clinical Phase I/II trial ReGenerate-1, with Diamyd Medical's patent-pending study drug Remygen™. In addition to evaluating the safety of the study drug, the trial will investigate Remygen's ability to regenerate insulin-producing beta cells in patients with diabetes who have little or no endogenous insulin production."The positive decision by the MPA is very pleasing and a significant milestone for us as a company as we now have two study drugs, Diamyd® and Remygen™, in clinical phase," says Ulf Hannelius, CEO of Diamyd